IQVIA Holdings Inc. (NYSE:IQV) Stock Position Lessened by Geode Capital Management LLC

Geode Capital Management LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.9% during the third quarter, Holdings Channel.com reports. The firm owned 4,097,543 shares of the medical research company’s stock after selling 124,448 shares during the period. Geode Capital Management LLC’s holdings in IQVIA were worth $967,585,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. FMR LLC raised its holdings in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. Impax Asset Management Group plc lifted its position in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares during the period. Finally, Legal & General Group Plc boosted its stake in IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after purchasing an additional 11,715 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on IQV shares. Robert W. Baird dropped their price objective on IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research note on Wednesday. Evercore ISI dropped their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $257.87.

IQVIA Price Performance

NYSE IQV opened at $201.05 on Thursday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $36.49 billion, a price-to-earnings ratio of 26.38, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The company has a 50 day simple moving average of $214.01 and a 200-day simple moving average of $224.77. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.